Database

Startups

Main Industry
Health Care
Main Product/Service
1. AJ201
2. AJ302
3. AJ303
Founded Year
2014
Unified Business No.
24777699
Status
Active
Number of Employees
0
Total Paid-in Capital
939,372,890 (NT$)
Location of Company
Taiwan , Taipei City
Exit Status
Emerging Stock Exchange(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Introduction
AnnJi Pharmaceutical is a clinical-stage drug development company that specializes in developing small molecules that address unmet medical needs in the areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, and SBMA (Spinal and bulbar muscular atrophy). Thefocus of the company is on creating global collaborations and business partnerships in the late-stage product development and commercialization of pharmaceutical drugs.



More ↓

Similar Companies

TRUST BIO-SONICS INC.

1. Ultrasound Imaging Agents
2. Ultrasound-Mediated Targeted Delivery

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention./Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases/Integrating cell therapy R&D and clinical applications through the FAST CGT platform to accelerate the development and commercialization

Acura NanoMedicine Corporation

1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2) three nanomedicine delivery platforms to engage in joint new drug development and licensing partnerships